Given that pharmacological FGF21 treatment has the capacity to reduce fat mass (21, 29), we next investigated if disruption of the normal regulation of FGF21 in FGF21-overexpressing mice could interfere with the anti-obesity effect of loading. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.